Why the study?
Does cyclophosphamide treatment increase the incidence of persistent CNS enterovirus infections and late paralysis in mice inoculated with attenuated human poliovirus?
Does cyclophosphamide treatment increase the incidence of persistent CNS enterovirus infections and late paralysis in mice inoculated with attenuated human poliovirus?
Cyclophosphamide treatment in mice inoculated with attenuated poliovirus serves as a model for persistent CNS enterovirus infections, leading to late paralysis and suppressed immune responses.
Answers are grounded in this paper and cite their sources.
CY immunosuppression increases clinical disease in poliovirus-inoculated mice; leaves open relevance to persistent human enterovirus infections.
An attenuated human poliovirus infection of cyclophosphamide (CY)-treated mice was developed as a model of persistent CNS enterovirus infections and as an investigation of the interaction of virus with motor neurons during persistence. Ten percent of mice inoculated intracerebrally with undiluted virus developed clinical disease by day 90, but of those treated with CY, 80% developed disease. At higher virus dilutions plus CY there was a marked increase in the incubation period. The latest onset of clinical disease occurred on day 146. Only paralyzed animals had pathologic changes in the spinal cord and virus antigen in anterior horn cells. Neutralizing antibodies were suppressed by CY, as were humoral and cellular immune responses to other antigens.
No takes yet. Share an insight, caveat, or question.
Jubelt et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: